Enanta Pharma (ENTA) Misses Q1 EPS by 39c

Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of ($1.48), $0.39 worse than the analyst estimate of ($1.09). Revenue for the quarter came in at $27.6 million versus the consensus estimate of $27.44 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Goldman "broadly" raises estimates for LTL and truckload stocks
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth